期刊
CLINICAL CARDIOLOGY
卷 34, 期 4, 页码 211-217出版社
WILEY
DOI: 10.1002/clc.20846
关键词
-
资金
- Scharper Therapeutics, Milan, Italy
Background: Studies have suggested that micronutrient deficiency has some role in the progression of chronic heart failure (CHF). Hypothesis: Oral supplementation with coenzyme Q(10) (CoQ(10)) and creatine may reduce mitochondrial dysfunction that contributes to impaired physical performance in CHF. Methods: We conducted a randomized, double-blind, placebo-controlled trial to determine the effect of a mixture of water-soluble CoQ(10) (CoQ(10) terclatrate; Q-ter) and creatine on exercise tolerance and health-related quality of life. Exercise tolerance was measured as total work capacity (kg.m) and peak oxygen consumption (VO2, mL/min/kg), both from a cardiopulmonary exercise test. Health-related quality of life was measured by the Sickness Impact Profile (SIP) in CHF secondary to left ventricular systolic dysfunction (left ventricular ejection fraction <= 35%). After baseline assessment, 67 patients with stable CHF were randomized to receive Q-ter 320 mg + creatine 340 mg (n=35) or placebo (n=32) once daily for 8 weeks. Results: At multivariate analysis, 8-week peak VO2 was significantly higher in the active treatment group than in the placebo group (+1.8 +/- 0.9 mL/min/kg, 95% CI: 0.1-3.6, P < 0.05). No untoward effects occurred in either group. Conclusions: This study suggests that oral Q-ter and creatine, added to conventional drug therapy, exert some beneficial effect on physical performance in stable systolic CHF. Results may support the design of larger studies aimed at assessing the long-term effects of this treatment on functional status and harder outcomes.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据